KING OF PRUSSIA, Pa., June 8, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage ...
KING OF PRUSSIA, Pa., April 18, 2023 /PRNewswire/ -- Global biotechnology leader CSL Behring today announced the U.S. Food and Drug Administration (FDA) approved a 50mL/10gm prefilled syringe for ...
Effects of NEPA (novel combination of netupitant and palonosetron) on ECG of healthy volunteers: A randomized, controlled, thorough ECG trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback